When is treatment indicated for Candida auris isolated from a urine culture?

Treatment of Candida auris in Urine

Treat Candida auris candiduria aggressively in most hospitalized patients, unlike other Candida species, due to the high risk of invasive spread, multidrug resistance, and mortality associated with this emerging pathogen.

Key Distinction: C. auris vs. Other Candida Species

While traditional IDSA guidelines recommend NOT treating asymptomatic candiduria for most Candida species unless patients are at high risk for dissemination (neutropenic, very low birth weight infants, or undergoing urologic procedures) 1, C. auris requires a different approach due to its unique characteristics 2:

• Difficult eradication and common environmental persistence
• Multidrug resistance patterns
• High propensity for nosocomial transmission
• Risk of progression to invasive disease even from urinary colonization 2

When to Treat C. auris Candiduria

High-Priority Treatment Indications (Treat Immediately):

• Symptomatic urinary tract infection with pyuria and clinical signs (dysuria, fever, flank pain) 3, 2
• Any neutropenic patient with C. auris in urine 1, 4
• Very low birth weight infants (<1500g) 1
• Patients undergoing urologic procedures (treat several days before and after) 1
• ICU patients or critically ill individuals with multiple comorbidities 3, 5
• Patients with indwelling urinary catheters, nephrostomy tubes, or suprapubic catheters 3, 2
• Patients with comorbidities including chronic kidney disease, diabetes mellitus, or immunosuppression 5

Consider Treatment Even if Asymptomatic:

Given C. auris's unique epidemiology, treatment should be considered for asymptomatic C. auris candiduria in hospitalized patients to prevent progression to invasive disease and limit transmission 2. This differs from the standard approach to other Candida species 1.

First-Line Treatment Recommendations

Preferred Agents:

Echinocandins are recommended as first-line therapy 2:

• Caspofungin: 70 mg loading dose, then 50 mg daily
• Micafungin: 100 mg daily
• Anidulafungin: 200 mg loading dose, then 100 mg daily

However, note the limitation: Recent data shows caspofungin demonstrated only 40% microbiological success and 10% overall success (including relapse/reinfection) for C. auris candiduria in hemato-oncology patients, with 30% developing resistance within 30 days 3. Despite this, echinocandins remain first-line due to C. auris's typical fluconazole resistance 2.

Alternative Agents:

Liposomal amphotericin B (3-5 mg/kg daily) is recommended as an alternative, particularly for:

• Suspected azole- and echinocandin-resistant infections 1
• Patients with treatment failure on echinocandins 2
• Pyelonephritis or upper tract involvement 2

Fluconazole should only be used if:

• Susceptibility testing confirms susceptibility (MIC <2 μg/mL) 2
• Most C. auris isolates are fluconazole-resistant (MIC ≥16 μg/mL), often carrying ERG11 Y132F mutation 6

Essential Concurrent Measures

Device Management:

• Remove indwelling bladder catheters whenever feasible 1
• Remove or replace nephrostomy tubes/stents if present 1
• Catheter removal is strongly recommended and may resolve candiduria without antifungal therapy for other Candida species, but C. auris often persists 1, 3

Infection Control (Critical for C. auris):

• Isolate the patient immediately 7
• Screen close contacts using composite axilla/groin swabs 7
• Environmental cleaning with sporicidal agents (hydrogen peroxide, peracetic acid, or chlorine-based disinfectants—NOT quaternary ammonium compounds) 7
• Repeated screening post-transfer from endemic areas, ideally within first 2 weeks 8

Treatment Duration

• Symptomatic UTI: Minimum 14 days after symptom resolution and catheter removal 1
• Recent data suggests shorter durations (7 days) may be adequate for non-auris Candida UTIs 9, but no data exist for C. auris—maintain 14-day duration given resistance concerns 2
• Pyelonephritis: 14 days minimum 1, 4

Monitoring and Follow-Up

• Repeat urine cultures every 2-3 days during treatment to document clearance 2
• Blood cultures if fever develops or patient deteriorates (rule out candidemia) 3, 2
• Surveillance cultures at 30 days post-treatment due to high relapse/reinfection rates (50-75% in some series) 3
• Susceptibility testing is mandatory for all C. auris isolates 1, 7

Salvage Therapy Options

For persistent or recurrent infection 2:

• Combination therapy: Echinocandin + liposomal amphotericin B
• Flucytosine 25 mg/kg four times daily (if susceptible, monitor for toxicity)
• Amphotericin B bladder irrigation (50 mg/L sterile water daily for 5 days) for fluconazole-resistant cystitis 1, 4

Common Pitfalls

• Do not assume fluconazole susceptibility—C. auris is typically resistant 6
• Do not treat C. auris candiduria like other Candida species—the "watch and wait" approach is inappropriate 2
• Do not neglect infection control measures—C. auris spreads readily in healthcare settings 7, 8
• Do not assume single negative screening excludes colonization—repeated screening is essential 8
• Be aware of mixed fungal populations with heterogeneous resistance patterns in the same patient 10